Immuneering (IMRX) CPO Leah Neufeld Buys 3,628 Shares via ESPP

What Happened
Leah Neufeld, Chief People Officer of Immuneering Corporation (IMRX), acquired 3,628 shares of Class A common stock on March 13, 2026 at $4.29 per share, for a total purchase value of $15,573. The acquisition was made through the company's 2021 Employee Stock Purchase Plan (ESPP) and is reported as an acquisition (transaction code A).

Key Details

• Transaction date: March 13, 2026 (Purchase Date under the ESPP).
• Price: $4.29 per share; total value $15,573.
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Footnotes:
  • F1: Reported voluntarily under the Immuneering 2021 ESPP; exempt under Rule 16b-3(c).
  • F2: Offering period ran Sept 16, 2025 – Mar 15, 2026; purchase occurred on the Purchase Date of Mar 13, 2026.
  • F3: Shares purchased at no less than 85% of the fair market value on the Purchase Date (ESPP discount).
• Filing timeliness: Form 4 filed on Mar 17, 2026, within the typical 2-business-day SEC filing window for Section 16 insiders.

Context
This was an ESPP purchase—employees often buy shares at a discounted price (here, at least a 15% discount to FMV). Such purchases are routine employee compensation/benefit transactions and can be interpreted as an insider acquiring stock, though the purchase size here (~$15.6k) is modest. The filing notes the transaction is exempt under Rule 16b-3(c), which commonly covers compensatory stock plans.